Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SNSS

Sunesis Pharmaceuticals (SNSS) Stock Price, News & Analysis

Sunesis Pharmaceuticals logo

About Sunesis Pharmaceuticals Stock (NASDAQ:SNSS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$2.38
$5.32
52-Week Range
N/A
Volume
1.20 million shs
Average Volume
4.33 million shs
Market Capitalization
$96.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive SNSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunesis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SNSS Stock News Headlines

Peter J Barris's Net Worth
AQSZF Aequus Pharmaceuticals Inc.
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
4 Breakout Stocks to Watch Going Into Labor Day
4 Stocks Under $10 to Trade Now
See More Headlines

SNSS Stock Analysis - Frequently Asked Questions

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) issued its earnings results on Sunday, November, 15th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.01.

Sunesis Pharmaceuticals shares reverse split before market open on Thursday, September 3rd 2020.The 1-10 reverse split was announced on Wednesday, September 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sunesis Pharmaceuticals investors own include SELLAS Life Sciences Group (SLS), Novavax (NVAX), NVIDIA (NVDA), QUALCOMM (QCOM), OPKO Health (OPK), TherapeuticsMD (TXMD) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
11/15/2020
Today
8/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SNSS
CIK
1061027
Fax
N/A
Employees
24
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$23.33 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-179.05%
Return on Assets
-72.27%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.74
Quick Ratio
7.74

Sales & Book Value

Annual Sales
$2.07 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.42 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
18,093,000
Free Float
N/A
Market Cap
$96.26 million
Optionable
Optionable
Beta
2.27
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:SNSS) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners